Selinexor + Placebo
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dedifferentiated Liposarcoma
Conditions
Dedifferentiated Liposarcoma
Trial Timeline
Jan 4, 2016 → Oct 26, 2021
NCT ID
NCT02606461About Selinexor + Placebo
Selinexor + Placebo is a phase 2/3 stage product being developed by Karyopharm Therapeutics for Dedifferentiated Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02606461. Target conditions include Dedifferentiated Liposarcoma.
What happened to similar drugs?
0 of 1 similar drugs in Dedifferentiated Liposarcoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
15
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02606461 | Phase 2/3 | Completed |
Competing Products
3 competing products in Dedifferentiated Liposarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 44 |
| Cabazitaxel | Sanofi | Phase 2 | 35 |
| INCMGA00012 + Palbociclib | Incyte | Phase 2 | 36 |